In November 2023, Dr. Max gained the Italian network Neo Apotek S.p.A. as part of the largest acquisition in the group’s history. This step increased the number of Italian branches of Dr. Max to over 210 pharmacies. Pre-acquisition, there were around 80 and, therefore, this expansion is significant. Dr. Max has now gained the position of an experienced leader in the pharmaceutical market.

Dr. Max was the main driver of portfolio growth for Penta in 2024, significantly boosting the average return of the entire fund. Together with other segments, such as Fortuna, Penta Hospitals, and banks, it contributed to the fund’s net profit of €621 million. Increased involvement in Italy reflects Penta’s broader strategies in healthcare sector expansion.

210+ pharmacies, which is almost threefold growth in Italy during 2023
14,000 m² distribution warehouse in Telgate, a modern logistics centre with planned automation
1+ million monthly visits to the drmax.it e-shop, digital channel becoming a key part of the business model
10+ million customers served annually by Dr. Max in Europe. Italy is becoming one of the largest markets in the network
EUR 4.4 billion Dr. Max group revenue for 2023

Expansion of Dr. Max into Italy through the Neo Apotek acquisition is a strategic healthcare sector move for Penta. This investment provides immediate access to a new market with 210+ pharmacies. Strengthening the long-term strategy of growth and digitalisation as well as an attractive combination of market reach and potential returns for investors.